Abstract
Summary
Sartans are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.
LPI (LP Information)' newest research report, the “Sartans Industry Forecast” looks at past sales and reviews total world Sartans sales in 2022, providing a comprehensive analysis by region and market sector of projected Sartans sales for 2023 through 2029. With Sartans sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sartans industry.
This Insight Report provides a comprehensive analysis of the global Sartans landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sartans portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Sartans market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sartans and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sartans.
The global Sartans market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Sartans is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Sartans is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Sartans is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Sartans players cover Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Sartans market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Segmentation by application
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Sartans market?
What factors are driving Sartans market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Sartans market opportunities vary by end market size?
How does Sartans break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Sartans Industry Forecast” looks at past sales and reviews total world Sartans sales in 2022, providing a comprehensive analysis by region and market sector of projected Sartans sales for 2023 through 2029. With Sartans sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sartans industry.
This Insight Report provides a comprehensive analysis of the global Sartans landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sartans portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Sartans market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sartans and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sartans.
The global Sartans market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Sartans is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Sartans is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Sartans is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Sartans players cover Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Sartans market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Segmentation by application
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Sartans market?
What factors are driving Sartans market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Sartans market opportunities vary by end market size?
How does Sartans break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Sartans Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Sartans by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Sartans by Country/Region, 2018, 2022 & 2029
2.2 Sartans Segment by Type
2.2.1 Valsartan
2.2.2 Telmisartan
2.2.3 Losartan
2.2.4 Irbesartan
2.2.5 Azilsartan
2.2.6 Olmesartan
2.3 Sartans Sales by Type
2.3.1 Global Sartans Sales Market Share by Type (2018-2023)
2.3.2 Global Sartans Revenue and Market Share by Type (2018-2023)
2.3.3 Global Sartans Sale Price by Type (2018-2023)
2.4 Sartans Segment by Application
2.4.1 Hypertension
2.4.2 Cardiovascular Diseases
2.4.3 Kidney Diseases
2.4.4 Other
2.5 Sartans Sales by Application
2.5.1 Global Sartans Sale Market Share by Application (2018-2023)
2.5.2 Global Sartans Revenue and Market Share by Application (2018-2023)
2.5.3 Global Sartans Sale Price by Application (2018-2023)
3 Global Sartans by Company
3.1 Global Sartans Breakdown Data by Company
3.1.1 Global Sartans Annual Sales by Company (2018-2023)
3.1.2 Global Sartans Sales Market Share by Company (2018-2023)
3.2 Global Sartans Annual Revenue by Company (2018-2023)
3.2.1 Global Sartans Revenue by Company (2018-2023)
3.2.2 Global Sartans Revenue Market Share by Company (2018-2023)
3.3 Global Sartans Sale Price by Company
3.4 Key Manufacturers Sartans Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Sartans Product Location Distribution
3.4.2 Players Sartans Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Sartans by Geographic Region
4.1 World Historic Sartans Market Size by Geographic Region (2018-2023)
4.1.1 Global Sartans Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Sartans Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Sartans Market Size by Country/Region (2018-2023)
4.2.1 Global Sartans Annual Sales by Country/Region (2018-2023)
4.2.2 Global Sartans Annual Revenue by Country/Region (2018-2023)
4.3 Americas Sartans Sales Growth
4.4 APAC Sartans Sales Growth
4.5 Europe Sartans Sales Growth
4.6 Middle East & Africa Sartans Sales Growth
5 Americas
5.1 Americas Sartans Sales by Country
5.1.1 Americas Sartans Sales by Country (2018-2023)
5.1.2 Americas Sartans Revenue by Country (2018-2023)
5.2 Americas Sartans Sales by Type
5.3 Americas Sartans Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Sartans Sales by Region
6.1.1 APAC Sartans Sales by Region (2018-2023)
6.1.2 APAC Sartans Revenue by Region (2018-2023)
6.2 APAC Sartans Sales by Type
6.3 APAC Sartans Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Sartans by Country
7.1.1 Europe Sartans Sales by Country (2018-2023)
7.1.2 Europe Sartans Revenue by Country (2018-2023)
7.2 Europe Sartans Sales by Type
7.3 Europe Sartans Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Sartans by Country
8.1.1 Middle East & Africa Sartans Sales by Country (2018-2023)
8.1.2 Middle East & Africa Sartans Revenue by Country (2018-2023)
8.2 Middle East & Africa Sartans Sales by Type
8.3 Middle East & Africa Sartans Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Sartans
10.3 Manufacturing Process Analysis of Sartans
10.4 Industry Chain Structure of Sartans
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Sartans Distributors
11.3 Sartans Customer
12 World Forecast Review for Sartans by Geographic Region
12.1 Global Sartans Market Size Forecast by Region
12.1.1 Global Sartans Forecast by Region (2024-2029)
12.1.2 Global Sartans Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Sartans Forecast by Type
12.7 Global Sartans Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Sartans Product Portfolios and Specifications
13.1.3 Pfizer Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Sartans Product Portfolios and Specifications
13.2.3 Novartis Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Sartans Product Portfolios and Specifications
13.3.3 Merck Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Astra Zeneca
13.4.1 Astra Zeneca Company Information
13.4.2 Astra Zeneca Sartans Product Portfolios and Specifications
13.4.3 Astra Zeneca Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Astra Zeneca Main Business Overview
13.4.5 Astra Zeneca Latest Developments
13.5 Jhonson and Johnson
13.5.1 Jhonson and Johnson Company Information
13.5.2 Jhonson and Johnson Sartans Product Portfolios and Specifications
13.5.3 Jhonson and Johnson Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Jhonson and Johnson Main Business Overview
13.5.5 Jhonson and Johnson Latest Developments
13.6 Eli Lilly
13.6.1 Eli Lilly Company Information
13.6.2 Eli Lilly Sartans Product Portfolios and Specifications
13.6.3 Eli Lilly Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Eli Lilly Main Business Overview
13.6.5 Eli Lilly Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Sartans Product Portfolios and Specifications
13.7.3 Sanofi Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 Bristol-Myers Squibb
13.8.1 Bristol-Myers Squibb Company Information
13.8.2 Bristol-Myers Squibb Sartans Product Portfolios and Specifications
13.8.3 Bristol-Myers Squibb Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bristol-Myers Squibb Main Business Overview
13.8.5 Bristol-Myers Squibb Latest Developments
13.9 Bayer
13.9.1 Bayer Company Information
13.9.2 Bayer Sartans Product Portfolios and Specifications
13.9.3 Bayer Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Bayer Main Business Overview
13.9.5 Bayer Latest Developments
13.10 GSK
13.10.1 GSK Company Information
13.10.2 GSK Sartans Product Portfolios and Specifications
13.10.3 GSK Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 GSK Main Business Overview
13.10.5 GSK Latest Developments
13.11 Teva Pharmaceutical
13.11.1 Teva Pharmaceutical Company Information
13.11.2 Teva Pharmaceutical Sartans Product Portfolios and Specifications
13.11.3 Teva Pharmaceutical Sartans Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Teva Pharmaceutical Main Business Overview
13.11.5 Teva Pharmaceutical Latest Developments
14 Research Findings and Conclusion